Phosphate binders are prescribed to chronic kidney disease (CKD) patients based on
associations of serum phosphate concentrations with mortality and calcification …

Convincing epidemiological data have repeatedly shown that increased phosphate levels
as well as generous phosphate intakes are associated with unfavourable outcome both in …

Rising levels of serum phosphate occur late in the course of chronic kidney disease (CKD)
and have been easy targets for nephrologists to treat using phosphate binding drugs, as …

Medicare costs for phosphate binders for US dialysis patients and patients with chronic
kidney disease enrolled in Medicare Part D exceeded $1.5 billion in 2015. Previous data …

The ideal serum level of phosphate in patients on dialysis, and the benefits of controlling
levels of phosphate in serum remain unclear despite observational studies that associate …

All-cause mortality and cardiovascular-related mortality have both been linked to abnormal
serum phosphate concentrations in chronic kidney disease (CKD). Aberrant serum …

In advanced renal disease, the kidney is unable to maintain phosphate balance due to
decreased urinary excretion as well as the imbalance of the bone metabolic axis. It is well …

Adequate phosphate management in end-stage CKD remains a mainstay of our therapeutic
approaches in this population, and additional promising drugs are in development and may …

Oral phosphate binder therapy is considered a'tower of strength'in the ever-expanding
armamentarium of drugs used to treat abnormal mineral metabolism in patients with chronic …

BACKGROUND: Phosphate binders are widely used to control serum phosphorus levels in
patients with chronic kidney disease (CKD). We analyzed the effects of phosphate binders …